Short answer
EyePoint, Inc. (EYPT) filed an 8-K current report with the SEC on March 2, 2026 reporting Item 8.01 (Other Events). Phase 3 trials (COMO & CAPRI) for DURAVYU in diabetic macular edema now enrolling: first patients dosed March 2, 2026.
EyePoint, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Phase 3 trials (COMO & CAPRI) for DURAVYU in diabetic macular edema now enrolling: first patients dosed March 2, 2026
- DME is a large market indication; Phase 3 initiation is a key de-risking milestone toward potential approval and commercialization
- Updated investor presentation posted simultaneously, likely reflecting revised timelines or data readout expectations
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other EyePoint, Inc. 8-K filings
Get the next EYPT 8-K as it lands
Follow EYPT for push alerts, or ask the research agent what this filing means.